Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

ClinicalTrials.gov ID: NCT00087035

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00087035. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Trial Of TAXOTERE + TARCEVA™ To Treat HRPC In Men ≥ 65 Years Of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining docetaxel with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel together with erlotinib works in treating older patients with progressive prostate cancer that has not responded to hormone therapy.

Study identification

NCT ID: NCT00087035
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Enrollment: 1 participant

Conditions and interventions

Conditions

Prostate Cancer

Interventions

docetaxel Drug
erlotinib hydrochloride Drug

Drug

Eligibility (public fields only)

Age range: 65 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2004 (Type not available)
Primary completion: Jun 2006 (Actual)
Completion: Mar 2008 (Actual)
Last update posted: Aug 3, 2020

2004 – 2008

United States locations

U.S. sites: 3
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center	Los Angeles	California	90048	—
Jonsson Comprehensive Cancer Center at UCLA	Los Angeles	California	90095-1781	—
University Cancer Center at University of Washington Medical Center	Seattle	Washington	98195-6043	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00087035, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 3, 2020 · Synced Nov 15, 2026